Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

NCT01690169
completedphase_1

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

NCT02094521
completedphase_1

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

NCT01978613
completedphase_1

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

NCT01967589

Clinical Trials (4)

Showing 4 of 4 trials
NCT01690169Phase 1

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Completed
NCT02094521Phase 1

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Completed
NCT01978613Phase 1

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

Completed
NCT01967589Phase 1

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4